WallStreetZenWallStreetZen

NASDAQ: ARTL
Artelo Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ARTL

Based on 1 analyst offering 12 month price targets for Artelo Biosciences Inc

Min Forecast
$18.00+1,284.62%
Avg Forecast
$18.00+1,284.62%
Max Forecast
$18.00+1,284.62%

Should I buy or sell ARTL stock?

Based on 1 analyst offering ratings for Artelo Biosciences Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ARTL stock forecasts and price targets.

ARTL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-26

1 of 1

Forecast return on equity

Is ARTL forecast to generate an efficient return?

Forecast return on assets

Is ARTL forecast to generate an efficient return on assets?

Company
-10.62%
Industry
120.22%
ARTL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARTL earnings per share forecast

What is ARTL's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$3.35
Avg 2 year Forecast
-$1.80
Avg 3 year Forecast
-$0.60

ARTL revenue forecast

What is ARTL's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$101.6M

ARTL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARTL$1.30$18.00+1,284.62%Strong Buy
ONCO$1.66N/AN/A
VRAX$0.38N/AN/A
ENVB$4.03N/AN/A
AZTR$0.28N/AN/A
View Top Biotech Stocks

Artelo Biosciences Stock Forecast FAQ

Is Artelo Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ARTL) stock is to Strong Buy ARTL stock.

Out of 1 analyst, 1 (100%) are recommending ARTL as a Strong Buy, 0 (0%) are recommending ARTL as a Buy, 0 (0%) are recommending ARTL as a Hold, 0 (0%) are recommending ARTL as a Sell, and 0 (0%) are recommending ARTL as a Strong Sell.

If you're new to stock investing, here's how to buy Artelo Biosciences stock.

What is ARTL's earnings growth forecast for 2026-2028?

(NASDAQ: ARTL) Artelo Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.57%.

Artelo Biosciences's earnings in 2026 is -$12,491,000.On average, 3 Wall Street analysts forecast ARTL's earnings for 2026 to be -$6,753,917, with the lowest ARTL earnings forecast at -$6,489,057, and the highest ARTL earnings forecast at -$6,952,561. On average, 3 Wall Street analysts forecast ARTL's earnings for 2027 to be -$3,624,053, with the lowest ARTL earnings forecast at -$3,481,933, and the highest ARTL earnings forecast at -$3,730,643.

In 2028, ARTL is forecast to generate -$1,214,881 in earnings, with the lowest earnings forecast at -$1,167,239 and the highest earnings forecast at -$1,250,613.

What is ARTL's revenue growth forecast for 2026-2028?

(NASDAQ: ARTL) Artelo Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.02%.

Artelo Biosciences's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ARTL's revenue for 2026 to be $0, with the lowest ARTL revenue forecast at $0, and the highest ARTL revenue forecast at $0. On average, 3 Wall Street analysts forecast ARTL's revenue for 2027 to be $0, with the lowest ARTL revenue forecast at $0, and the highest ARTL revenue forecast at $0.

In 2028, ARTL is forecast to generate $205,003,656 in revenue, with the lowest revenue forecast at $196,967,028 and the highest revenue forecast at $211,039,707.

What is ARTL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ARTL) forecast ROA is -10.62%, which is lower than the forecast US Biotechnology industry average of 120.22%.

What is ARTL's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ARTL price target, the average ARTL price target is $18.00, with the highest ARTL stock price forecast at $18.00 and the lowest ARTL stock price forecast at $18.00.

The Wall Street analyst predicted that Artelo Biosciences's share price could reach $18.00 by Aug 26, 2026. The average Artelo Biosciences stock price prediction forecasts a potential upside of 1,284.62% from the current ARTL share price of $1.30.

What is ARTL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ARTL) Artelo Biosciences's current Earnings Per Share (EPS) is -$20.90. On average, analysts forecast that ARTL's EPS will be -$3.35 for 2026, with the lowest EPS forecast at -$3.21, and the highest EPS forecast at -$3.44. On average, analysts forecast that ARTL's EPS will be -$1.80 for 2027, with the lowest EPS forecast at -$1.72, and the highest EPS forecast at -$1.85. In 2028, ARTL's EPS is forecast to hit -$0.60 (min: -$0.58, max: -$0.62).

What is ARTL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ARTL) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.